- Home
- BBIO vs YUMC Comparison
BBIO vs YUMC Comparison
Compare BBIO & YUMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | YUMC |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 15.6B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | BBIO | YUMC |
|---|---|---|
| Price | $74.32 | $47.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 21 | 0 |
| Target Price | ★ $78.43 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 1.0M |
| Earning Date | 02-19-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 2.02% |
| EPS Growth | N/A | ★ 6.57 |
| EPS | N/A | ★ 2.40 |
| Revenue | $353,780,000.00 | ★ $11,569,000,000.00 |
| Revenue This Year | $127.64 | $5.49 |
| Revenue Next Year | $78.38 | $5.68 |
| P/E Ratio | ★ N/A | $19.85 |
| Revenue Growth | ★ 62.46 | 3.29 |
| 52 Week Low | $28.10 | $41.00 |
| 52 Week High | $78.59 | $53.99 |
Technical Indicators
Market Signals| Indicator | BBIO | YUMC |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 52.39 |
| Support Level | $71.19 | $46.56 |
| Resistance Level | $75.57 | $48.42 |
| Average True Range (ATR) | 2.44 | 0.71 |
| MACD | -0.65 | -0.16 |
| Stochastic Oscillator | 38.54 | 48.52 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About YUMC Yum China Holdings Inc.
With more than 16,000 units and almost USD 12 billion in systemwide sales in 2024, Yum China is the largest restaurant operator in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (11,648 units) and Pizza Hut (3,724), but the company's portfolio also includes other brands such as Little Sheep, Taco Bell, Huang Ji Huang, and Lavazza (collectively representing more than 1,000 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.